Back to search results

Enhancing Attention in Elderly Using a Brain-Computer-Interface

This study is exploring whether non-invasive brain stimulation, called transcranial electrical stimulation (tACS), and mindfulness meditation can improve attention and memory in adults. Researchers believe these interventions might strengthen your brain's ability to maintain thinking skills as you age, even if you have mild cognitive impairment (MCI). The study will measure changes in brain activity related to attention during different intervention sessions. You may be eligible if you are between 18 and 90 years old, have good general health (for younger adults), or have normal vision and no current dementia diagnosis (for older adults). The study is currently unclear about its recruitment status and aims to enroll 100 participants.

Study design
This interventional study plans to enroll 100 participants. It is not specified if it is randomized or blinded.
What's involved
You will participate in either transcranial electrical stimulation (tACS) or mindfulness meditation sessions. Electroencephalography (EEG) signals will be recorded while you perform n-back tasks.
Compensation
Not stated in the trial record.
Follow-up
Your brain activity will be measured from enrollment to the end of the study, which is 3 days for young adults and 8 days for older adults.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07441122

Enhancing Attention in Elderly Using a Brain-Computer-Interface

Recruiting
NAAges 18–90InterventionalTreatment
University of Texas at Austin
~100 participants
Updated 2026-07-27 on ClinicalTrials.gov
What's tested:transcranial electrical stimulationMindfulness Meditation

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in neural correlates of attention across different intervention sessions
Measured over From enrollment to the end of the study after 3 days (young adults) or 8 days (older adults)

Conditions

Mild Cognitive Impairment (MCI)

Explore related trials

Mild cognitive disorder

NCT07441122

Where you'd take part

This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Sun City

    Georgetown, Texasstudy coordinator listed

    Recruiting

  • The University of Texas at Austin

    Austin, Texasstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Jose del R. Millan, PhD
[email protected]
512-232-8111
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Good general health.
Normal or corrected vision.
no history of neurological/psychiatric disease
ability to read and understand English
ability to understand information and ability to give a free and informed consent
Normal or corrected vision.
Self-reports no current diagnosis of dementia.
Ability to provide written/electronic, informed consent.

Exclusion

Neurological or psychiatric diseases that could be contraindicated for tACS (e.g., personal history of epilepsy/seizure brain damage, history of fainting, bipolar disorder, schizophrenia, current substance use disorder, etc.).
Medications that elevate seizure threshold (e.g., stimulant medication, high dose bupropion).
Factors hindering EEG acquisition and tACS delivery (e.g., skin infection, wounds, dermatitis, inability to access the scalp of the participant).
Neurological or psychiatric diseases that could be contraindicated for tACS (e.g., personal history of epilepsy/seizure brain damage, pacemakers, history of fainting, bipolar disorder, schizophrenia, current substance use disorder, etc.).
Medications that elevate seizure threshold (e.g., stimulant medication, high dose bupropion).
Factors hindering EEG acquisition and tACS delivery (e.g., skin infection, wounds, dermatitis, inability to access the scalp of the participant).
Diagnosis of dementia.
Do not have the capacity to provide informed consent.

What this trial measures

  • Change in neural correlates of attention across different intervention sessionsFrom enrollment to the end of the study after 3 days (young adults) or 8 days (older adults)

    This outcome measures whether neural correlates of attentional markers (e.g. amplitude, peak-to-peak, band power and connectivity measures of neural correlates) change across sessions as a result of intervention.